Safety and response after peptide receptor radionuclide therapy with ¹⁷⁷Lu‐DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial

Atsushi Kudo, Seigo Kinuya, Ryoichi Yoshimura et al.|Journal of Hepato-Biliary-Pancreatic Sciences|2021

Cited by 19